How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

907 results for

Medication Causes of Dyspepsia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Management of Opioid Therapy (OT) for Chronic Pain

prescriptions were still written in 2012.[11] The increase in opioid prescribing is matched by a parallel increase in morbidity, mortality, opioid-related overdose death rates, and substance use disorders (SUD) treatment admissions from 1999 to 2008.[12,13] In 2009, drug overdose became the leading cause of injury-related death in the U.S., surpassing deaths from traffic accidents.[14] In 2014, 1.9 million Americans were affected by an OUD related to non-medical use of prescription pain relievers,[15 (...) , Washington, DC & Office of Evidence Based Practice, U.S. Army Medical Command Version 3.0 – 2017 Based on evidence reviewed through December 2016V A / D o D Cli ni cal P r a cti ce G ui d el i n e f o r O p ioid T h e r a p y for Ch r on ic Pa in February 2017 Page 3 of 198 Table of Contents I. Introduction 5 II. How to Use This Clinical Practice Guideline 6 7 10 11 12 13 14 15 15 16 16 19 20 21 21 26 26 27 27 31 III. Recommendations IV. Algorithm A. Module A: Determination of Appropriateness for Opioid

2017 VA/DoD Clinical Practice Guidelines

122. Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable?

: Extra one in 2000 women over eight years. 10 o Pneumonia. 11 o Vitamin B12 and magnesium deficiencies. 12,13 • Abruptly stopping PPIs may cause transient rebound GERD or dyspepsia symptoms. 14,15 o Tapering may help. 6 • Long-term PPIs should be considered for patients with recurrent symptoms, endoscopic esophagitis, complications from GERD (example: stricture), or those requiring gastroprotection. Authors: Michael R. Kolber BSc MD CCFP MSc, Tony Nickonchuk BSc Pharm Disclosure: Authors do not have (...) Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca

2017 Tools for Practice

123. Dyslipidaemias (Full text)

Article Contents Article Navigation 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias Alberico L Catapano (Chairperson) (Italy) Corresponding authors: Alberico L. Catapano, Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, and Multimedica IRCCS (MI) Italy. Tel: +39 02 5031 8401, Fax: +39 02 5031 8386, E-mail: ; Ian Graham, Cardiology Department, Hermitage Medical Clinic, Old Lucan Road, Dublin 20, Dublin, Ireland. Tel: +353 1 (...) 6459715, Fax: +353 1 6459714, E-mail: Search for other works by this author on: Ian Graham (Chairperson) (Ireland) Corresponding authors: Alberico L. Catapano, Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, and Multimedica IRCCS (MI) Italy. Tel: +39 02 5031 8401, Fax: +39 02 5031 8386, E-mail: ; Ian Graham, Cardiology Department, Hermitage Medical Clinic, Old Lucan Road, Dublin 20, Dublin, Ireland. Tel: +353 1 6459715, Fax: +353 1 6459714

2016 European Society of Cardiology PubMed

124. Treatment of Helicobacter pylori Infection

. L e o n tiadis , MD , PhD 2 , C o lin W . H o w den , MD , F A C G 3 a n d S t e v en F . M os s , MD , F A C G 4 Helicobacter pylori ( H. pylori ) infection is a common worldwide infection that is an important cause of peptic ulcer disease and gastric cancer. H. pylori may also have a role in uninvestigated and functional dyspepsia, ulcer risk in patients taking low-dose aspirin or starting therapy with a non-steroidal anti-in? ammatory medication, unexplained iron de? ciency anemia (...) advances have been made in the arena of medical treatment. Th us, this guideline is intended to provide clinicians working in North America with updated recommendations on the treatment of H. pylori infection. For the purposes of this document, we have defi ned North America as the United States and Canada. When- ever possible, recommendations are based upon the best available evidence from the world’s literature with special attention paid to literature from North America. When evidence from North

2017 American College of Gastroenterology

125. Musculoskeletal Strains and Sprains - Guidelines for Prescribing NSAIDs

Other medications -- some medications can cause pain as a side effect (see below) Musculoskeletal strains and sprains are assessed based on history and the presence of pain and swelling. Rule out the following conditions that may present with similar signs and symptoms: Fracture - indicated by marked bruising, swelling, deformity, bone tenderness, or inability to bear weight. Tendon rupture - indicated by inability to move muscle. Cartilage injury - indicated by tearing sensation, severe pain (...) a GI disorder such as ulcers: Naproxen or diclofenac Medium risk: Ketoprofen Lowest risk: Ibuprofen, celecoxib Other safety concerns Renal impairment: If CrCl <30 ml/min, avoid use of NSAIDs. Those with less compromised renal function may use NSAIDs short-term, but caution is still required, especially if they are on other medications such as diuretics or ACE-inhibitors. Pulmonary effects: NSAIDs can induce an asthma attack in some patients. ASA is the most common cause, and COX-2 inhibitors have

2017 medSask

126. Gastro-oesophageal reflux disease in children and young people: diagnosis and management

that causes symptoms (for example, discomfort or pain) severe enough to merit medical treatment, or to gastro-oesophageal reflux-associated complications (such as oesophagitis or pulmonary aspiration). In adults, the term GORD is often used more narrowly, referring specifically to reflux oesophagitis. Mark Marked distress ed distress There is very limited evidence, and no objective or widely accepted clinical definition, for what constitutes 'marked distress' in infants and children who are unable (...) subsequent treatment. 1.3.7 Do not offer metoclopramide, domperidone or erythromycin to treat GOR or GORD without seeking specialist advice and taking into account their potential to cause adverse events. 1.4 Enteral tube feeding for GORD 1.4.1 Only consider enteral tube feeding to promote weight gain in infants and children with overt regurgitation and faltering growth if: other explanations for poor weight gain have been explored and/or and/or recommended feeding and medical management of overt

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

127. Gallstone disease: diagnosis and initial management

population are thought to have gallstone disease, and most of these people experience no symptoms. For a small proportion of people with gallstone disease, the stones irritate the gallbladder or block part of the biliary system, and this can cause symptoms such as pain, infection and inflammation. If these symptoms are left untreated, gallstones can cause more serious and in some cases life-threatening conditions such as cholecystitis, cholangitis, pancreatitis and jaundice. There is variation in how (...) their symptoms until they have their gallbladder or gallstones removed. 1.4.2 Advise people that they should not need to avoid food and drink that triggered their symptoms after they have their gallbladder or gallstones removed. 1.4.3 Advise people to seek further advice from their GP if eating or drinking triggers existing symptoms or causes new symptoms to develop after they have recovered from having their gallbladder or gallstones removed. Gallstone disease: diagnosis and management (CG188) © NICE 2018

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

128. LINX® reflux management system

as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for a health professional's advice. It must not be relied upon without verification from authoritative sources. Queensland Health does not accept any liability, including for any injury, loss or damage, incurred by use of or reliance on the information. This Brief was commissioned by Queensland Health, in its role as the Secretariat (...) stomach contents from entering the LOS. 2, 3 The LINX device permits natural physiologic function to enable swallowing or release of elevated gastric pressure (associated with belching or vomiting). 1 This is achieved when the peristaltic pressure of the food bolus, for example, is greater than the magnetic attraction between adjacent beads of the LINX System, causing them to expand and ‘open’ the device. As the food moves through the oesophagus into the stomach and the peristaltic pressure drops

2016 COAG Health Council - Horizon Scanning Technology Briefs

129. MASCC and ESMO Consensus Guidelines for the Prevention of Chemotherapy and Radiotherapy-Induced Nausea and Vomiting

,TheNetherlands introduction Despite the considerable progress achieved in the last 30 years, vomiting and, especially, nausea, continue to be twoof the most distressing side-effects of cancer chemotherapy. In the late 1990s, several professional organisations published recommen- dations on the optimal antiemetic prophylaxis in patients sub- mitted to chemotherapy and/or radiotherapy. The European Society of Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC (...) with ondansetron plus dexamethasone (48% versus 12%) [59]. The second trial compared ondansetron plus aprepitant with/ Volume27 | Supplement5 | September2016 doi:10.1093/annonc/mdw270 | v??? AnnalsofOncology clinicalpracticeguidelineswithout dexamethasone versus ondansetron plus placebo with/ without dexamethasone [60]. A complete response rate (no vomiting, no retching and no use of rescue medications) of 65% was reported in the ondansetron plus aprepitant arm versus 51% in the ondansetron arm for the ?rst 24

2017 European Society for Medical Oncology

130. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients (Full text)

, 4, 6962 Viganello-Lugano, Switzerland. E-mail: and/or to The MASCC Office. E-mail: Search for other works by this author on: R. J. Gralla 5Albert Einstein College of Medicine, Jacobi Medical Center, New York * Correspondence to: c/o ESMO Guidelines Committee, ESMO Head Office, Via Luigi Taddei, 4, 6962 Viganello-Lugano, Switzerland. E-mail: and/or to The MASCC Office. E-mail: Search for other works by this author on: E. Bruera 6Department of Palliative, Rehabilitation and Integrative Medicine (...) , Johannesburg, South Africa * Correspondence to: c/o ESMO Guidelines Committee, ESMO Head Office, Via Luigi Taddei, 4, 6962 Viganello-Lugano, Switzerland. E-mail: and/or to The MASCC Office. E-mail: Search for other works by this author on: J. Roscoe 15Department of Surgery, University of Rochester Medical Center, Rochester, USA * Correspondence to: c/o ESMO Guidelines Committee, ESMO Head Office, Via Luigi Taddei, 4, 6962 Viganello-Lugano, Switzerland. E-mail: and/or to The MASCC Office. E-mail: Search

2016 International Society for Oral Oncology PubMed

131. Lymphangioleiomyomatosis Diagnosis and Management Part I: An Official ATS/JRS Clinical Practice Guideline

reported to recur in transplanted lungs, consistent with a metastatic mechanism for the disease (14, 15), but has not been reported to cause graft failure or to jeopardize eligibility for transplant. Genetic studies have revealed clonal origins for neoplastic cells harvested from pulmonary and extrapulmonary lesions of individual patients (16, 17). The neoplastic cells that in?ltrate the lung in patients with LAM have smooth muscle characteristics and a benign histological appearance (18), arise from (...) , important, or not important (27). LiteratureSearchandStudySelection In collaboration with an ATS methodologist (J.L.B.), a search strategy was designed using medical subject heading keywords and text words. The searches were limited to human studies and articles in English or in any language with English abstracts. A librarian from the National Institute of Health (K.S.) performedtheinitialliteraturesearchin2009. Four databases were searched: MEDLINE, EMBASE, Web of Science, and Scopus. AMERICAN

2016 American Thoracic Society

132. Management of Acute and Recurrent Gout: A Clinical Practice Guideline from the American College of Physicians (Full text)

in patients with acute gout. These drugs have known anti-inflammatory activity and have been shown to reduce pain in many conditions. Further, they have been successfully used to prevent gout flares during urate-lowering therapy. The main harms of NSAIDs are gastrointestinal adverse effects ranging from minor (dyspepsia) to serious (perforations, ulcers, and bleeding). Long-term use of higher doses can cause chronic renal insufficiency. Corticosteroids There were no placebo-controlled trials of oral (...) publication, or once an update has been issued. Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. Financial Support: Financial support for the development of this guideline comes exclusively from the ACP operating budget. Disclosures: Dr. Barry reports grants and personal fees from the Informed Medical Decisions Foundation and Healthwise outside the submitted work. Dr. Boyd reports royalties from UpToDate outside the submitted

2016 American College of Physicians PubMed

133. Screening and Management of Lipids

obtaining data. Assess ASCVD risk factors • Clinical atherosclerotic cardiovascular disease (ASCVD includes stroke; peripheral arterial disease; coronary heart disease). • LDL-C = 190 mg/dL and age = 21,not caused by drugs or underlying medical condition (Table 1). • Diabetes mellitus type 1 or 2, age 40-75 years of age with LDL-C 70-189 mg/dL. • 10-year ASCVD risk = 7.5% for ages 40-75years (see Table 2 for calculation information). • CKD.(If CKD, see the UMHS CKD guideline for managing lipids in CKD (...) , but have had no effect on mortality, and in some instances have been associated with increased adverse events. For this reason, they are considered second line medications for CHD prevention and are primarily reserved for patients with severe triglyceride elevation (> 500 mg/dl) despite lifestyle changes to prevent pancreatitis. Adverse effects are generally GI, including nausea, dyspepsia, and change in bowel habits. The risk of cholestasis and cholecystectomy is increased. Fibrates carry a small risk

2016 University of Michigan Health System

134. Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease

(GORD) is a common problem. It is caused by conditions that disturb the sphincter function at the lower end of the oesophagus, such as a hiatus hernia. Symptoms of GORD can be broadly grouped into those directly related to reflux episodes, such as heartburn, regurgitation, chest pain and nausea, and those caused by complications of the disease, including dysphagia and respiratory difficulties. Repeated episodes of GORD can damage the lining of the oesophagus and lead to oesophageal ulceration (...) , oesophageal stricture and Barrett's oesophagus. Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (IPG585) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 82.2 A NICE clinical guideline describes recommendations for the investigation and management of GORD and dyspepsia in adults. The standard treatments for symptomatic GORD are lifestyle modification and drug therapy. Patients

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

135. Myocardial infarction: cardiac rehabilitation and prevention of further MI

Is treatment with an oral anticoagulant, aspirin and clopidogrel preferable to treatment with an oral anticoagulant and clopidogrel in people who have had an MI, have an indication for oral anticoagulation and are treated either medically, by primary PCI or by coronary artery bypass grafting surgery? 26 2.4 What characteristics are associated with uptake and adherence to cardiac rehabilitation after an acute MI when rehabilitation is started early? 26 2.5 In people who have had a STEMI who undergo primary (...) guidance 80. The recommendations are labelled according to when they were originally published (see About this guideline for details). Myocardial infarction (MI) is one of the most dramatic presentations of coronary artery disease. It is usually caused by blockage of a coronary artery producing tissue death and consequently the typical features of a heart attack: severe chest pain, changes on the electrocardiogram (ECG), and raised concentrations of proteins released from the dying heart tissue

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

136. Idiopathic pulmonary fibrosis in adults: diagnosis and management

be documented. See the General Medical Council's Good practice in prescribing and managing medicines and devices for further information. Where recommendations have been made for the use of drugs outside their licensed indications ('off-label use'), these drugs are marked with a footnote in the recommendations. Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights (...) ://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 22Best supportive care Offer best supportive care to people with idiopathic pulmonary fibrosis from the point of diagnosis. Best supportive care should be tailored to disease severity, rate of progression, and the person's preference, and should include if appropriate: information and support (see recommendation 1.3.1) symptom relief management of comorbidities withdrawal of therapies suspected to be ineffective or causing harm end of life

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

137. Trastuzumab (Ogivri) - breast cancer or stomach cancer

infusion only. If an alternate route of administration is required, other trastuzumab products offering such an option should be used In order to prevent medication errors it is important to check the vial labels to ensure that the medicinal product being prepared and administered is trastuzumab and not trastuzumab emtansine. 4 Posology Metastatic breast cancer Three-weekly schedule The recommended initial loading dose is 8 mg/kg body weight. The recommended maintenance dose at three-weekly intervals (...) 2 ). The incidence of symptomatic cardiac dysfunction was 1.7 % in the trastuzumab arm. Clinical experience is limited in patients above 65 years of age. Infusion-related reactions (IRRs) and hypersensitivity Serious IRRs to trastuzumab infusion including dyspnoea, hypotension, wheezing, hypertension, bronchospasm, supraventricular tachyarrhythmia, reduced oxygen saturation, anaphylaxis, respiratory distress, urticaria and angioedema have been reported (see section 4.8). Pre-medication may

2019 European Medicines Agency - EPARs

138. Obese, overweight with risk factors: liraglutide (Saxenda)

with severe hepatic impairment, people with congestive heart failure class III to IV and people with obesity secondary to endocrine or eating disorders or obesity caused by another medicinal treatment. The SPC also recommends that liraglutide is not recommended for use in people with inflammatory bowel disease and diabetic gastroparesis. See the liraglutide (Saxenda) SPC for further details. The following are reported as very common (1 in 10 or more) adverse reactions in the liraglutide (Saxenda) SPC (...) : nausea, vomiting, diarrhoea and constipation. Common adverse reactions (from 1 in 100 to 1 in 10) reported in the SPC include hypoglycaemia, insomnia, dizziness, dysgeusia, dry mouth, dyspepsia, gastritis, gastro-oesophageal reflux disease, flatulence, eructation, upper abdomen pain, abdomen distension, cholelithiasis, injection site reactions, asthenia, fatigue, increased lipase and increased amylase. The EPAR for liraglutide (Saxenda) reported that the general adverse event profile is in-line

2017 National Institute for Health and Clinical Excellence - Advice

139. Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates

gastrointestinal adverse effects than intravenous bisphosphonates and some people may find them difficult to swallow. Nevertheless, some people may prefer oral medication because a hospital visit is not required. Zoledronic acid is administered intravenously and, it may be easier for some people to adhere to 6-monthly intravenous treatment, rather than daily oral treatment. Zoledronic acid infusion can cause an acute response resulting in flu-like symptoms. Calcium and vitamin D supplementation is generally (...) mortality (absolute reductions 1.4%, 1.1% and 1.7% respectively), but not breast cancer recurrence or all-cause mortality. When prespecified subgroup analyses according to menopausal status were undertaken, no benefits were seen in premenopausal women, but the benefits in postmenopausal women were found to be greater than in the general study population. At 10 years compared with control, the absolute reductions in the risk of breast cancer mortality, bone recurrence and all-cause mortality

2017 National Institute for Health and Clinical Excellence - Advice

140. Management of osteoporosis and the prevention of fragility fractures

in Scotland. The majority of fractures occur in people over the age of 65 and a large proportion of these patients have osteoporosis. Fractures are an important cause of morbidity, and patients who suffer hip fractures and vertebral fractures have a decreased life expectancy compared with population-based controls. A wide range of treatments that can reduce the risk of fractures occurring in patients with osteoporosis is now available. These have the potential to improve clinical outcomes for patients (...) with osteoporosis and to reduce societal costs of medical care associated with fractures. 1.2 REMIT of THE GuIDElINE 1.2.1 OvERALL OBjECTIvES This guideline provides recommendations based on current evidence for best practice in the management of osteoporosis and prevention of fractures. It addresses risk factors for fracture, commonly-used tools for assessment of fracture risk, approaches to targeting therapy, pharmacological, and non-pharmacological treatments to reduce fracture risk, treatment of painful

2015 SIGN

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>